David S Goldstein Selected Research

3,4-Dihydroxyphenylacetic Acid

1/2018	Cerebrospinal fluid biomarkers of central dopamine deficiency predict Parkinson's disease.
10/2016	Elevated cerebrospinal fluid ratios of cysteinyl-dopamine/3,4-dihydroxyphenylacetic acid in parkinsonian synucleinopathies.
1/2013	Biomarkers, mechanisms, and potential prevention of catecholamine neuron loss in Parkinson disease.
8/2009	Relative efficiencies of plasma catechol levels and ratios for neonatal diagnosis of menkes disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David S Goldstein Research Topics

Disease

76	Parkinson Disease (Parkinson's Disease) 01/2022 - 08/2002
43	Orthostatic Hypotension (Postural Hypotension) 01/2021 - 11/2002
36	Multiple System Atrophy 01/2021 - 07/2002
33	Pure Autonomic Failure 01/2021 - 08/2002
20	Synucleinopathies 01/2022 - 02/2007
19	Parkinsonian Disorders (Parkinsonism) 01/2021 - 09/2003
17	Pheochromocytoma 01/2018 - 03/2002
15	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2022 - 02/2008
14	Dementia (Dementias) 11/2020 - 11/2011
12	Neoplasms (Cancer) 01/2010 - 03/2002
10	Movement Disorders (Movement Disorder) 01/2020 - 11/2003
10	Hypertension (High Blood Pressure) 02/2016 - 05/2002
8	Autonomic Nervous System Diseases (Dysautonomia) 01/2020 - 06/2003
8	Dizziness (Lightheadedness) 05/2015 - 02/2002
7	Menkes Kinky Hair Syndrome (Menkes Disease) 09/2018 - 02/2008
6	Lewy Body Disease (Lewy Body Dementia) 01/2018 - 03/2009
5	Orthostatic Intolerance 01/2019 - 11/2002
5	REM Sleep Behavior Disorder 01/2019 - 11/2011
5	Anosmia 01/2019 - 01/2010
4	Alzheimer Disease (Alzheimer's Disease) 01/2022 - 06/2003
4	Cognitive Dysfunction 01/2022 - 04/2011
3	Heart Failure 03/2022 - 11/2002
3	Syncope (Fainting) 01/2019 - 01/2003
3	dopamine beta hydroxylase deficiency 01/2019 - 06/2012
3	Hypothermia 09/2008 - 01/2002
3	von Hippel-Lindau Disease (von Hippel Lindau Disease) 05/2007 - 10/2005
3	Multiple Endocrine Neoplasia Type 2a (MEN 2) 05/2007 - 10/2005
3	Vasovagal Syncope 09/2006 - 06/2002
2	Neurodevelopmental Disorders 01/2018 - 08/2009
2	Disease Progression 11/2017 - 11/2003
2	Hypotension (Low Blood Pressure) 08/2009 - 09/2006
2	Paraganglioma (Paragangliomas) 04/2005 - 01/2003
2	Tachycardia (Tachyarrhythmias) 11/2004 - 11/2002
2	Schizophrenia (Dementia Praecox) 11/2004 - 08/2002
2	Shy-Drager Syndrome 06/2004 - 07/2002
1	Inflammation (Inflammations) 01/2022
1	Rare Diseases (Rare Disease) 10/2020
1	COVID-19 01/2020
1	Hemorrhage 01/2020

Drug/Important Bio-Agent (IBA)

43	Norepinephrine (Noradrenaline)FDA LinkGeneric 01/2022 - 02/2002
36	CatecholaminesIBA 01/2022 - 01/2002
33	Dopamine (Intropin)FDA LinkGeneric 01/2022 - 11/2003
23	hydroxide ionIBA 01/2021 - 06/2003
18	alpha-SynucleinIBA 01/2021 - 04/2004
16	Biomarkers (Surrogate Marker)IBA 01/2022 - 02/2007
15	Proteins (Proteins, Gene)FDA Link 01/2022 - 10/2005
10	SynucleinsIBA 01/2022 - 04/2004
9	Epinephrine (Adrenaline)FDA LinkGeneric 09/2008 - 01/2003
7	3,4-dihydroxyphenylacetaldehydeIBA 06/2021 - 12/2012
6	Neurotransmitter Agents (Neurotransmitter)IBA 10/2020 - 11/2002
6	CatecholsIBA 01/2019 - 06/2003
6	CopperIBA 09/2018 - 02/2008
5	TyramineIBA 02/2016 - 10/2004
5	3,4-dihydroxyphenylglycolIBA 01/2010 - 11/2004
5	NormetanephrineIBA 04/2005 - 01/2003
4	Aldehyde DehydrogenaseIBA 01/2022 - 08/2014
4	Vesicular Monoamine Transport Proteins (Vesicular Monoamine Transporter)IBA 01/2022 - 12/2004
4	3,4-Dihydroxyphenylacetic AcidIBA 01/2018 - 08/2009
4	Dihydroxyphenylalanine (Dopa)IBA 09/2015 - 08/2004
4	Messenger RNA (mRNA)IBA 01/2015 - 10/2005
4	Levodopa (L Dopa)FDA LinkGeneric 10/2014 - 11/2003
4	MetanephrineIBA 04/2005 - 01/2003
3	Tyrosine 3-Monooxygenase (Tyrosine Hydroxylase)IBA 01/2022 - 03/2003
3	Pharmaceutical PreparationsIBA 01/2022 - 06/2005
3	Monoamine Oxidase (MAO)IBA 11/2017 - 02/2016
3	EnzymesIBA 01/2016 - 08/2003
3	Edrophonium (Tensilon)FDA LinkGeneric 05/2015 - 10/2004
3	Adrenergic Agents (Adrenergic Drugs)IBA 01/2013 - 05/2002
3	Glucagon (Glukagon)FDA Link 01/2010 - 09/2008
3	Yohimbine (Yocon)IBA 11/2008 - 07/2002
3	Aromatic-L-Amino-Acid DecarboxylasesIBA 12/2004 - 03/2003
3	Adrenergic Receptors (Adrenergic Receptor)IBA 05/2003 - 06/2002
2	Norepinephrine Plasma Membrane Transport Proteins (Norepinephrine Transporter)IBA 01/2022 - 10/2005
2	RotenoneIBA 01/2022 - 04/2015
2	VaccinesIBA 01/2020 - 01/2020
2	DroxidopaIBA 01/2019 - 05/2010
2	Selegiline (E250)FDA LinkGeneric 11/2017 - 09/2016
2	Cholinergic Agents (Cholinergics)IBA 05/2015 - 10/2004
2	AldehydesIBA 03/2015 - 01/2012
2	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA 07/2014 - 09/2003
2	Adenosine Triphosphatases (ATPase)IBA 02/2013 - 05/2002
2	Copper-Transporting ATPasesIBA 09/2012 - 08/2009
2	Transcription Factors (Transcription Factor)IBA 07/2012 - 08/2006
2	fluorodopa F 18IBA 11/2011 - 01/2010
2	ProdrugsIBA 01/2011 - 05/2010
2	catechol (pyrocatechol)IBA 08/2009 - 12/2004
2	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA 08/2009 - 03/2009
2	AntibodiesIBA 03/2009 - 12/2006
2	Trimethaphan (Trimetaphan)IBA 11/2008 - 10/2004
2	Isoproterenol (Isoprenaline)FDA LinkGeneric 11/2008 - 09/2008
2	AminesIBA 04/2005 - 01/2003
2	Amino Acids FDA Link 12/2004 - 08/2003
2	FludrocortisoneIBA 08/2003 - 11/2002
1	CytokinesIBA 01/2022
1	Atomoxetine Hydrochloride (Strattera)FDA LinkGeneric 01/2022
1	OsteoprotegerinIBA 01/2022
1	GoldIBA 01/2020

Therapy/Procedure

25	Sympathectomy (Sympathectomies) 01/2019 - 08/2002
17	Denervation 01/2019 - 09/2003
5	Therapeutics 03/2022 - 08/2003